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Tosylation and mesylation of adenine (1) at room temperature give
regioselectively N9-sulfonylated purines 2 and 5. Excess of TsCl or
MsCl at higher reaction temperatures leads to formation of unsta-
ble N6,N9-disulfonylated products 3 and 6, which easily transform
into the corresponding N6-monosulfonylated product 4. Two N-sul-
fonylated purine nucleoside derivatives 12 and 15 have also been
prepared. 1D/2D NMR determined the site of sulfonylation and the
spatial arrangement of the substituents. MS spectra showed unex-
pected rearrangement of protonated molecular ions that occurs upon
the loss of SO2.
Key words: synthesis, N9-sulfonyl, N6-sulfonyl, N6, N9-disulfonyl
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INTRODUCTION
Modified nucleosides and nucleic acid bases have been the subject of
many studies due to their potential activity as enzyme inhibitors resulting
in antitumor1 and antiviral2 activity. Sulfonamide group R1SO2-NHR2 is a
common pharmacophore in various biologically active molecules, enzyme in-
hibitors and receptor antagonists.3 Recently, we have reported the synthesis
of a series of pyrimidine nucleic base derivatives possessing sulfonamide
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pharmacophore, which showed promising in vitro antitumor activity.4–6 These
results directed our interest toward N-sulfonyl derivatives of purine nucleic
bases as new candidates for compounds with antitumor activity. This type of
compounds has received very limited attention in the literature. Martiro-
syan et al.7 reported the preparation of N9-tosyladenine in 81% yield and
Zemlicka et al.8 obtained the same compound (50% yield) in the reaction of
adenallene with p-toluenesulfonyl chloride. It is known that the nucleoside
adenosine exerts its physiological actions through activation of four distinct
subtypes of cell surface receptors, recently classified as A1, A2a, A2b, and A3.
9
Structural modification at N6 of adenosine leads to selective A1 agonists
10,11
while modification at C-2 confers high potency and selectivity on A2a recep-
tors.12 With respect to these observations, it also appeared of interest to in-
vestigate the approach to N6- and C-2-aminosulfonyl derivatives of adeno-
sine. In the present work, we report the synthesis and NMR and MS studies
of novel N9- and N6-mono- and N6, N9-di-sulfonyladenine derivatives and the
synthesis of two sulfonylated purine nucleoside derivatives.
RESULTS AND DISCUSSION
Synthesis
Following the Martirosyan procedure,7 adenine (1) was reacted with 2
eq. of p-toluenesulfonyl chloride (TsCl) in pyridine (20 oC, 70 h). The N9-
(p-toluenesulfonyl)adenine (2) was isolated in 60% yield (Scheme 1). Reac-
tion of adenine (1) with a large excess of TsCl (5 eq./ pyridine, 20 h) at 80 oC
gave a mixture of unreacted 1 (26%), N9-tosyladenine 2 (7%), N6,N9-bis(to-
syl)adenine 3 (2–17%) and N6-(tosyl)adenine 4 (3–12%). Formation of sulfo-
nylated products in low yields despite a large excess of TsCl indicates their
decomposition at elevated temperature. Prolonged reaction time (96 hours
at 80 oC) gave only monosubstituted derivatives 2 (20% yield) and 4 (55%
yield) as a consequence of the transformation of the initially formed bis-sul-
fonylated 3 into mono-sulfonylated 4. The bis-sufonylated derivative 3 was
also found to transform into 4 by alcoholysis (MeOH, EtOH) during the iso-
lation procedure or by standing of alcohol solutions at room temperature.
The attempted preparation of 3 in higher yield by reaction of 2 and TsCl
gave a mixture of 3 (13% yield) and 4 (40% yield). Reaction of adenine (1)
with 2–6 eq. of MsCl in pyridine, at room temperature, afforded only N9-me-
syladenine 5 in 90% yield; at higher reaction temperature, a considerable
decomposition of 5 was observed. In the reaction of N9-tosyladenine 2 with 6
eq. of MsCl, transsulfonylation was observed, giving 5 (33% yield) and ade-
nine (1) (43% yield) instead of the expected N6-mesyl-N9-tosyl derivative or
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N6-mesyl derivative. However, the N6-tosyl derivative 4 reacts with MsCl
giving N6-(p-toluenesulfonyl)-N9-(methanesulfonyl)adenine (6); the 1H NMR
spectrum of the crude product corresponds to 6 countering the trace of
pyridine. N6,N9-Disubstituted 6 also easily transforms into the N6-tosyl de-
rivative 4 by methanolysis at room temperature.
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Scheme 1
Scheme 2
The investigated tosylation and mesylation reactions of 1 reveal that at
room temperature sulfonylation can be performed regioselectively at N-9 (2,
60% yield; 5, 90% yield). However, excess of TsCl or MsCl at higher reaction
temperatures leads to formation of unstable N6,N9-disulfonylated products
3 and 6 which easily transform into the corresponding N6-monosulfonylated
product 4. Instability of the N9-sulfonyl group is obvious from the observed
transsulfonylation of 2 to 5 and fast alcoholysis of 3 and 6 at room tempera-
ture into the mono-sulfonylated product 4. In contrast, N6-sulfonylated
products are more stable since no desulfonylation or removal by alcoholysis
could be observed. It seems that the presence of the N6-Ts increases the in-
stability of N9-sulfonyl group of 3 and 6 through strong electron withdraw-
ing effects. In order to examine the influence of the N6-acyl group on the
yield of N9-sulfonylation, N6-benzoyladenine13 (7) was prepared (Scheme 2).
The reaction of 7 and TsCl gave N6-benzoyl-N9-(p-toluenesulfonyl)adenine
(8) in 76% yield; with MsCl, N6-benzoyl-N9-(methanesulfonyl)adenine (9)
was obtained in 94% yield. Thus, considerably higher yields of N9-sulfony-
lated products could be obtained with the weaker electron withdrawing
N6-benzoyl group. However, both 8 and 9 are still very sensitive, giving
starting compound 7 upon chromatographic purification on silica gel or
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Scheme 3
upon recrystallization from alcohol. By ammonolysis (NH3/MeOH) compound
9 transforms first into N6-benzoyladenine (7) and then into debenzoylated
1, as revealed by TLC monitoring of the reaction.
The synthetic route to N-sulfonylated nucleosides 12 and 15 is outlined
in Scheme 3; the synthetic steps comprise protection of hydroxyl groups,
sulfonylation of amino function and deprotection. Protected adenosine14 10
and 9-(2,3,5-tri-O-acetyl-ß-D-ribofuranosyl)-2-aminopurine (13) were treated
with TsCl in pyridine to give 9-(2,3,5-tri-O-acetyl-ß-D-ribofuranosyl)-N6-(p-
toluenesulfonyl)adenosine (11) in 50% yield and 9-(2,3,5-tri-O-acetyl-ß-D-
ribofuranosyl)-2-N-(p-toluenesulfonyl)aminopurine (14) in 47% yield. Depro-
tection of sulfonylated nucleosides 11 and 14 by methanolic ammonia afforded
N6-(p-toluenesulfonyl)adenosine (12) in 99% yield and 9-(ß-D-ribofuranosyl)-
2-N-(p-toluenesulfonyl)aminopurine (15) in 98% yield.
NMR Spectra
In order to determine the positions of N-sulfonylation in 2, 4 and 5, we
used the 1D and 2D NMR methods. Structures of the N9-substituted com-
pounds 2, 5 and the N6-substituted compound 4 were first deduced from
their 1H NMR spectra. The most striking difference refers to N-protons and
purine skeleton hydrogen atoms, H-2 and H-8. In both spectra of N9-sulfo-
nylated 2 and 5, two amino protons at C-6, readily exchangeable for deute-
rium by addition of D2O, appear as singlets at 7.68 and 7.70 ppm, respec-
tively. In 2 and 5, H-2 is more shielded (8.23 and 8.29 ppm) than H-8 (8.62
and 8.41 ppm). The H-8 and H-2 assignments were confirmed by car-
bon-proton connectivity in the 1H/13C heteronuclear correlation spectra
(HETCOR). Thus, signals at 138.43 and 154.64 ppm in the 13C NMR spectra
of N9-tosyladenine 2 correspond to C-8 and C-2, respectively, with one-bond
C-H coupling constants of 225 Hz (1JC-8,H) and 204 Hz (
1JC-2,H), which is in
agreement with literature data.16 Additionally, in the NOESY spectrum of
2, the assignment of H-8 was proved by its interaction with phenyl (Ph-b)
protons (Figure 1).
Contrary to 2 and 5, in the N6-substituted compound 4, the H-8 (8.30
ppm) and H-2 (8.37 ppm) signals changed positions and the H-2 signal
decreased in intensity. In the 1H NMR spectra of N6-tosyladenine 4, two broad-
ened one-proton singlets at 13.60 and 12.80 ppm, both exchangeable with
D2O, were observed. No splitting between these N-protons was observed in
1D spectra, while COSY and NOESY spectra showed no cross-peaks. There-
fore, the observed signals for N-protons are not due to the chemically non-
-equivalent geminal N-protons but to protons at two different N-atoms in 4.
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Figure 1. NOESY spectrum of N9-(p-toluenesulfonyl)adenine (2).
Figure 2. NOESY spectrum of N6-(p-toluenesulfonyl)adenine (4).
The NH-6 and NH-9 signals were identified by interaction of NH-9 with
H-8, which can be shown in part of the NOESY spectrum (Figure 2).
It has to be emphasized that the N7-substituted product was disre-
garded, since in the hypothetical N7-substituted molecule two broad signals
for non-equivalent geminal NH2 protons, displaying cross-peaks in COSY
and NOESY spectra, should be observed.
Mass Spectra
The 70 eV EI mass spectra at 100 s and 1 s time delay of
N9-monosulfonylated products 2 and 5, N6-monosulfonylated products 4
and 11, and N6,N9-disulfonylated products 3, 8 and 9 are shown in the Ex-
perimental section (Table II).
Analysis of the mass spectra shows the characteristic behavior of these
compounds under electron impact: a) under the 1 s time delay conditions the
formation of stable M+H+ species is strongly preferred and fragment ions
of low abundance are detected in their mass spectra, and b) these com-
pounds show evidence of skeletal rearrangement of molecular ions by the
appearance of M-SO2
+ and M-SO2H
+ ions. Their compositions are checked
by high resolution measurements for compounds 2 and 4 (Table I).
CONCLUSIONS
N9-Tosyl purine 2 and N9-mesyl purine 5 have been prepared
regioselectively by tosylation and mesylation reactions of 1 at room temper-
ature (2, 60% yield; 5, 90% yield). Excess of TsCl or MsCl at higher reaction
temperatures leads to formation of unstable N6,N9-disulfonylated products
3 and 6, which easily transform into the corresponding N6-monosulfonyl-
ated product 4. 1D/2D NMR determined the site of sulfonylation and the
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TABLE I
High-resolution mass measurement data for M-SO2 
+ of compounds 2 and 4
compound m/z measured value calculated value elemental composition
2 225 225.093369 225.100896 C12H11N5
4 225 225.089105 225.100896 C12H11N5
spatial arrangement of the substituents. Two N-sulfonylated purine nucleo-
side derivatives, N6-(p-toluenesulfonyl)adenosine (12) and 9-(ß-D-ribofura-
nosyl)-2-N-(p-toluenesulfonyl)aminopurine (15) have also been prepared in
satisfactory yields. MS spectra showed unexpected rearrangement of
protonated molecular ions that occurs upon the loss of SO2.
EXPERIMENTAL
General
Solvents were distilled from appropriate drying agents shortly before use. TLC
was carried out on Merck precoated glass plates or DC-plastikfolien Kieselgel 60 F254
and preparative thick layer (2 mm) chromatography on Merck 60 F254. Flash column
chromatography was performed on silica gel Merck 0.040–0.063 mm. Melting points
were determined on a Kofler hot-stage apparatus and are uncorrected. UV Spectra
max/nm, log /dm3 mol–1 cm–1 were taken on a Philips PU8700 UV/VIS spectrophoto-
meter. IR Spectra were obtained for KBr pellets on a Perkin-Elmer 297 spectrophoto-
meter.
The 1H and 13C NMR spectra were recorded on a Varian Gemini 300 spectrome-
ter, operating at 75.46 MHz for the 13C nucleus. The samples were dissolved in
DMSO-d6 or CDCl3 and measured at 20 C in 5 mm NMR tubes. Sample concentra-
tions were 0.1 M for 1H and 0.2 M for 13C measurements. Chemical shifts (/ppm)
are referred to TMS. Digital resolution was 0.3 Hz per point in 1H and 0.5 Hz per
point in 13C NMR one-dimensional spectra. The applied techniques were standard
1H and 13C with broadband proton decoupling, 13C gated decoupling, COSY, NOESY
and HETCOR. For proton decoupling, the Waltz-16 modulation was used. The COSY
spectra were recorded in the magnitude mode with 1024 points in F2 dimension and
256 increments in F1 dimension, zero-filled to 1024 points. Increments were mea-
sured with 16 scans, 4500 Hz spectral width and a relaxation delay of 0.8 s. The cor-
responding digital resolution was 8.9 Hz per point and 17.6 Hz per point in F2 and
F1 dimensions, respectively. The NOESY spectra were recorded in a phase-sensitive
mode and at mixing times of 0.450.80 s. All other measurement parameters were as
for the COSY spectra. The HETCOR spectra were recorded with 2048 points in F2
dimension and 256 increments in F1 dimension zero-filled to 512 points. Each incre-
ment was recorded by 96 scans with a relaxation delay of 1.0 s. Spectral widths were
19000 Hz in F2 and 4500 Hz in F1 dimensions, and the corresponding digital resolu-
tions were 18.6 Hz per point and 17.6 Hz per point, respectively.
All mass spectrometric investigations were performed using a Fourier transform
mass spectrometer ThermoQuest FT/MS 2001 DD (Madison, WI, USA) equipped with
a 3 T superconducting magnet. Following the electron impact (EI) ion formation at
70 eV, a time delay of 100 s or 1 s was employed for relaxation of the initial cyclo-
tron and axial motions by collision with background neutrals. The samples were in-
troduced by direct insertion.
Reactions of adenine (1) with p-toluenesulfonyl chloride (TsCl)
1) Adenine (1) (135 mg, 1.00 mmol) was suspended in anhydrous pyridine (5 mL)
and TsCl (380 mg, 2.00 mmol) was added. After stirring at room temperature for 70
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hours, the solvent was evaporated under reduced pressure. Ethanol was added to
the residual yellow solid and the resulting white solid was filtered off. Recrystalli-
zation from ethanol yielded N 9-(p-toluenesulfonyl)adenine (2)7 170 mg (60%);
m.p. = 206–207 C (lit. m.p. = 206–207 C); Rf = 0.57 (CH2Cl2/MeOH 9:1).
Additional data for N9-(p-toluenesulfonyl)adenine (2): UV (MeOH) max/nm: 254.9
(shoulder), 237.1 and 205.5; log / dm3 mol–1 cm–1: 4.14, 4.25 and 4.38; IR (KBr)
max/cm–1: 3310 (m), 3160 (m), 3040 (w), 2920 (w), 1680 (s), 1670 (m), 1600 (s), 1570
(m), 1480 (m), 1385 (m), 1290 (m, doublet), 1190 (s), 1180 (s), 1160–1150 (s, doublet);
1H NMR (DMSO-d6) /ppm: 8.62 (s, 1H, H-8), 8.23 (s, 1H, H-2), 8.09 (d, 2H, J = 8.1
Hz, Ph-b), 7.68 (s, 2H, NH2), 7.49 (d, 2H, J = 8.1 Hz, Ph-c), 2.37 (s, 3H, CH3); 13C
NMR (DMSO-d6) /ppm: 156.59 (s, C-6), 154.64 (d, C-2), 148.65 (s, Ph-a), 146.94 (s,
C-4), 138.43 (d, C-8), 133.83 (s, Ph-d), 130.55 (d, Ph-c), 128.31 (d, Ph-b), 119.02 (s,
C-5), 21.22 (q, CH3).
2) Adenine (1) (135 mg, 1.00 mmol) was suspended in anhydrous pyridine (8 mL)
and TsCl (950 mg, 5.00 mmol) was added. After stirring at 80 C for 20 hours, the re-
sulting yellow solution was evaporated under reduced pressure. The residue was
treated with methanol and the resulting solid was filtered off, yielding 75 mg (17%)
of N 6, N 9-bis(p-toluenesulfonyl)adenine (3). The filtrate was evaporated and purified
by preparative chromatography (CH2Cl2/MeOH 20:1) yielding N9-(p-toluenesulfonyl)ad-
enine (2) 20 mg (7%), adenine (1) 35 mg (26%) and N 6-(p-toluenesulfonyl)adenine (4)
9 mg (3%).
N 6,N 9-Bis(p-toluenesulfonyl)adenine (3): m.p. = 245 C; Rf = 0.73 (CH2Cl2/MeOH
9:1); UV (MeOH) max/nm: 269.6 (shoulder), 233.5 and 203.2; log / dm3 mol–1 cm–1:
3.99, 4.06 and 4.30; IR (KBr) max/cm–1: 3460–3400 (br, w), 3120 (w), 3080 (w),
2960–2920 (w), 2820 (w), 1640 (s, doublet), 1590 (s, doublet), 1490 (w), 1435 (m),
1390 (s), 1315 (s), 1295 (m), 1195 (s), 1180 (s), 1170 (s), 1155 (s). 1H NMR (DMSO-d6)
/ppm: 12.70 (brs, 1H, NH), 8.77 (s, 1H, H-8), 8.40 (s, 1H, H-2), 8.03 (d, 2H, J = 8.0
Hz, Ph-b), 7.82 (d, 2H, J = 8.0 Hz, Ph-b’), 7.45 (d, 2H, J = 8.3 Hz, Ph-c), 7.30 (d, 2H,
J = 7.7 Hz, Ph-c’), 2.33 (s, 3H, CH3), 2.30 (s, 3H, CH3); 13C NMR (DMSO-d6) /ppm:
156.00 (s, C-6), 152.55 (d, C-2), 151.52 (s, C-4 or Ph-a), 148.51 (s, Ph-a or C-4), 147.09
(d, C-8 or Ph-d or Ph-d'), 141.86 (s, Ph-a’), 139.29 (s, Ph-d or Ph-d' or C-8), 133.65 (s,
Ph-d or Ph-d' or C-8), 130.62 (d, Ph-c), 129.08 (d, Ph-c'), 128.31 (d, Ph-b), 127.18 (d,
Ph-b'), 123.26 (s, C-5), 21.25 (q, CH3), 20.99 (q, CH3).
3) Adenine (1) (135 mg, 1.00 mmol) was suspended in anhydrous pyridine (8 mL)
and TsCl (950 mg, 5.00 mmol) was added. After stirring at 80 C for 96 hours, the re-
sulting dark yellow solution was evaporated under reduced pressure. The residue
was purified by preparative chromatography on a funnel (CH2Cl2/MeOH 25:1) yield-
ing N 9-(p-toluenesulfonyl)adenine (2) 58 mg (20%) and N 6-(p-toluenesulfonyl)adeni-
ne (4) 160 mg, (55%).
N 6-(p-toluenesulfonyl)adenine (4): m.p. = 305 C; Rf = 0.31 (CH2Cl2/MeOH 9:1);
UV (MeOH) max/nm: 291.1 and 208.0 (shoulder); log / dm3 mol–1 cm–1: 4.60 and
4.61; IR (KBr) max/cm–1: 3500–3400 (br, w), 3140 (w), 3060–2940 (br, w), 2820 (w),
1630 (s), 1620 (m), 1595 (s), 1500 (m), 1450 (m), 1365 (s), 1350 (s), 1280 (m), 1170 (s);
1H NMR (DMSO-d6) /ppm: 13.60 (brs, 1H, NH-9), 12.80 (brs, 1H, NH-6), 8.37 (brs,
1H, H-2), 8.30 (s, 1H, H-8), 7.85 (d, 2H, J = 8.1 Hz, Ph-b’), 7.36 (d, 2H, J = 8.1 Hz,
Ph-c’), 2.36 (s, 3H, CH3); 13C NMR (300 MHz), (DMSO-d6) /ppm: 145.80 ( very broad
signal, C-2), 144.50 (very broad signal C-8), 142.72 (s, Ph-a’), 140.34 (s, Ph-d’), 129.69
(d, Ph-c’), 126.36 (d, Ph-b’), 21.02 (q, CH3). Signals for C-6, C-4, and C-5 are missing.
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13C NMR (600 MHz), (DMSO-d6) /ppm: 156.70 (very broad signal, C-6), 145.90
(very broad signal, C-2), 144.34 (very broad signals C-8+C-4), 142.30 (s, Ph-a’), 140.04
(s, Ph-d’), 129.29 (d, Ph-c’), 126.01 (d, Ph-b’), 113.93 (very broad signal, C-5), 20.80
(q, CH3).
Anal. calcd. for C12H11N5O2S1 (Mr = 289.32): C 49.82, H 3.83, N 24.21%; found: C
49.79, H 3.34, N 24.41%.
Reaction of N9-(p-toluenesulfonyl)adenine (2)
with p-toluenesulfonyl chloride (TsCl)
N 9-Tosyladenine 2 (140 mg, 0.48 mmol) was dissolved in anhydrous pyridine (5
mL) and TsCl (185 mg, 0.97 mmol) was added. The solution was stirred at 20 C for
three days and treated with another amount of TsCl (185 mg, 0.97 mmol). The reac-
tion mixture was stirred at 80 C for three more days. The reaction mixture con-
tained derivatives 3, 4 and decomposition products, as seen from the TLC plate
(CH2Cl2/MeOH 15:1). From this mixture, N 6,N 9-bis(p-toluenesulfonyl)adenine (3) 28
mg (13%) and N 6-(p-toluenesulfonyl)adenine (4) 56 mg (40%) were isolated by pre-
parative chromatography (CH2Cl2/MeOH 15:1).
Reaction of N9-(p-toluenesulfonyl)adenine (2)
with methanesulfonyl chloride (MsCl)
N 9-Tosyladenine 2 (200 mg, 0.69 mmol) was dissolved in anhydrous pyridine (7
mL) and MsCl (0.11 mL, 1.38 mmol) was added. The solution was stirred at 80 C for
three hours and during that time another two portions of MsCl (2  0.11 mL) were
added. The dark brown solution was evaporated to dryness and the residue was pu-
rified by preparative chromatography (CH2Cl2/MeOH 9:1), yielding N 9-(methane-
sulfonyl)adenine (5) 48 mg (33%), and adenine (1) 40 mg (43%).
N9-(methanesulfonyl)adenine (5)
Adenine (1) (200 mg, 1.54 mmol) was suspended in anhydrous pyridine (8 mL)
and MsCl (0.24 mL, 3.08 mmol) was added into the reaction mixture at 0 C. After
stirring at room temperature for 48 hours, the solvent was evaporated. The residue
was treated with ethanol and the resulting white solid was filtered off. Recrystal-
lization from ethanol yielded N9-(methanesulfonyl)adenine (5) 296 mg (90%) as white
crystals: m.p. = 228–230 C; Rf = 0.37 (CH2Cl2/MeOH 9:1); UV (MeOH) max/nm: 256.1
(shoulder) and 207.6; log / dm3 mol–1 cm–1: 3.80 and 3.88; IR (KBr) max/cm–1: 3300
(m), 3140 (m), 3040 (w), 3000 (w), 2920 (w), 1670 (s), 1610 (m), 1570 (m), 1470 (m),
1350 (s), 1330 (m), 1275 (m), 1185 (s), 1160 (s), 1145 (s); 1H NMR (DMSO-d6) /ppm:
8.41 (s, 1H, H-8), 8.29 (s, 1H, H-2), 7.70 (s, 2H, NH2), 3.78 (s, 3H, CH3). 13C NMR
(DMSO-d6) /ppm: 156.58 (s, C-6), 154.45 (d, C-2), 148.76 (s, C-4), 137.89 (d, C-8),
119.02 (s, C-5), 41.99 (q, CH3).
Anal. calcd. for C6H7N5O2S1 (Mr = 213.22): C 33.80, H 3.31, N 32.85%; found: C
33.93, H 3.52, N 32.80%.
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N6-(p-toluenesulfonyl)-N9-(methanesulfonyl)adenine (6)
A mixture of N6-(p-toluenesulfonyl)adenine (4) (100 mg, 0.35 mmol) and MsCl
(0.054 mL, 0.69 mmol) in anhydrous pyridine (4 mL) was stirred at room tempera-
ture for 24 hours. The solvent was evaporated and the mixture was treated with di-
chloromethane and hexane. The resulting solid was filtered off, yielding the starting
material 4 (60 mg). Another crystallization of the mother liquor (adding hexane)
yielded product 6 (ca. 40 mg, 32%) mixed with pyridine which stabilized the product:
Rf = 0.50 (CH2Cl2/MeOH 9:1); 1H NMR (DMSO-d6) /ppm: 8.88 (d, 2H, J = 6.0 Hz,
Py’s H-2 and H-6), 8.52 (m, 1H, Py’s H-4), 8.34 (s, 1H, H-8), 8.26 (s, 1H, H-2), 8.01 (t,
2H, J = 6.5 Hz, Py’s H-3 and H-5), 7.82 (d, 2H, J = 7.3 Hz, Ph-b), 7.33 (d, 2H, J = 7.9
Hz, Ph-c), 3.60 (brs, NH+H2O), 2.32 (s, 3H, CH3), 2.30 (s, 3H, CH3).
N6-benzoyladenine13 (7)
Additional data: 1H NMR (DMSO-d6) /ppm: 12.46 (brs, 1H, NH-9), 11.53 (brs,
1H, NH-6), 8.76 (brs, 1H, H-2), 8.54 (s, 1H, H-8), 8.13 (d, 2H, J = 8.1 Hz, Ph-b’), 7.67
(m, 1H, Ph-d’), 7.57 (m, 2H, Ph-c’). The NH-6 signal was identified by interaction
with the Ph-b’ protons in the NOESY spectrum, and the NH-9 signal was identified
by interaction with the Ph-c’ proton in the LR-COSY spectrum. 13C NMR (DMSO-d6)
/ppm: 166.91 (s, C=O), 162.0 (broad signal, C-6), 151.50 (d, C-2), 146.29 (brs, C-8),
145.50 (broad signal, C-4), 133.13 (s, Ph-a’), 132.99 (d, Ph-d’), 128.88 (d, Ph-b’ or Ph-c’),
128.78 (d, Ph-b’ or Ph-c’), 115.00 (broad signal, C-5).
N6-Benzoyl-N9-(p-toluenesulfonyl)adenine (8)
A mixture of N6-benzoyladenine13 (7) (200 mg, 0.84 mmol) and TsCl (192 mg,
1.00 mmol) in anhydrous pyridine (5 mL) was stirred at –5 C to +5 C. Another
amount of TsCl (127 mg, 0.67 mmol) was added after 20 min and the solution was
stirred at 5 C for 45 minutes. The residue was treated with dichloromethane (5 mL)
and extracted with water. The organic layer was dried over Na2SO4, evaporated to
one half of the volume without heating, and treated with hexane. The resulting
white solid was filtered off, yielding N6-benzoyl-N9-(p-toluenesulfonyl)adenine (8)
250 mg (76%): m.p. = 160 C; Rf = 0.78 (CH2Cl2/MeOH 9:1); UV (MeOH) max/nm:
277.4, 235.2, 206.3 and 204.9; log / dm3 mol–1 cm–1: 4.41, 4.48, 4.60 and 4.61; IR
(KBr) max/cm–1: 3185 (w), 3140 (w), 3090 (w), 3040 (w), 2910 (w), 1990–1850 (br, vw),
1690 (w-m), 1594 (m), 1568 (m), 1490 (s), 1380–1365 (m, doublet), 1235 (br, m), 1190
(m), 1175 (s), 1140 (s). 1H NMR (CDCl3) /ppm: 9.00 (brs, 1H, NH-6), 8.87 (s, 1H,
H-2), 8.48 (s, 1H, H-8), 8.18 (d, 2H, J = 7.9 Hz, Ph-b), 8.00 (d, 2H, J = 7.7 Hz, Ph-c),
7.62 (m, 1H, Ph-d’), 7.52 (m, 2H, Ph-c’), 7.40 (d, 2H, J = 7.9 Hz, Ph-b’), 2.45 (s, 3H,
CH3); 13C NMR (CDCl3) /ppm: 164.60 (s, C=O), 153.88 (d, C-2), 150.55 (s, C-6), 149.99
(s, C-4), 147.03 (s, Ph-a), 140.15 (s, Ph-d), 133.22 (s, Ph-a’), 132.86 (d, C-8), 130.09 (d,
Ph-c), 128.68 (d, Ph-c’), 128.49 (d, Ph-b’), 127.76 (d, Ph-b), 125.74 (d, Ph-d’), 123.38 (s,
C-5), 21.64 (q, CH3).
N6-Benzoyl-N9-(methanesulfonyl)adenine (9)
A mixture of N 6-benzoyladenine13 (7) (200 mg, 0.84 mmol) and MsCl (0.13 mL,
1.68 mmol) in anhydrous pyridine (5 mL) was stirred at room temperature. Another
amount of MsCl (0.13 mL) was added after one hour. The suspension was stirred at
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room temperature for 2.5 hours and the solvent was evaporated. The resulting solid
was treated with ethanol, filtered off, to give 250 mg (94%) of N 6-benzoyl-N 9-(me-
thanesulfonyl)adenine (9) (Any recrystallization leads to decomposition of product 9
to the starting material 7): m.p. = 171 C; Rf = 0.58 (CH2Cl2/MeOH 9:1). UV (MeOH)
max/nm: 277.9, 228.9, 205.5, 196.4 and 192.8; log / dm3 mol–1 cm–1: 4.17, 3.95, 4.23,
3.86 and 3.85; IR (KBr) max/cm–1: 3305 (m), 3280 (m), 3090 (m), 3010 (m), 2920 (w),
1955 (vw), 1805 (vw), 1690 (s), 1600 (s), 1580 (s), 1500–1480 (s, doublet), 1370 (s),
1340 (m), 1270 (s), 1250 (s), 1185 (s), 1160 (s); 1H NMR (DMSO-d6) /ppm: 11.50 (brs,
1H, NH-6), 8.94 (s, 1H, H-2), 8.74 (s, 1H, H-8), 8.07 (d, 2H, J = 7.4 Hz, Ph-b’), 7.68
(m, 1H, Ph-d’), 7.58 (m, 2H, Ph-c’), 3.89 (s, 3H, CH3); 13C NMR (DMSO-d6) /ppm:
170.20 (s, C=O), 166.76 (s, C-6), 156.10 (s, C-4), 151.87 (d, C-2), 144.70 (s, Ph-a’),
133.50 (d, Ph-d’), 133.22 (d, C-8), 128.73 (d, Ph-c’), 128.71 (d, Ph-b’), 114.29 (s, C-5),
40.10 (q, CH3).
9-(2,3,5-Tri-O-acetyl-ß-D-ribofuranosyl)-N6-(p-toluenesulfonyl)adenosine (11)
A mixture of 9-(2,3,5-tri-O-acetyl-ß-D-ribofuranosyl)adenosine14 (10) (100 mg, 0.25
mmol) and TsCl (171 mg, 0.88 mmol) in anhydrous pyridine (11 mL) was stirred at
80 C for 4 days. During this time, three portions of TsCl (3  171 mg) were added
(total amount of TsCl was 684 mg, 3.50 mmol). The dark yellow solution was evapo-
rated and the residue was purified by preparative chromatography on a funnel
(CH2Cl2/MeOH 30:1), yielding 9-(2,3,5-tri-O-acetyl-ß-D-ribofuranosyl)-N 6-(p-toluene-
sulfonyl)adenosine (11) 68 mg (50%): m.p. = 113 C; Rf = 0.60 (CH2Cl2/MeOH 9:1); UV
(MeOH) max/nm: 274.4 (shoulder), 202.3 (shoulder) and 192.1; log / dm3 mol–1 cm–1:
3.63, 3.51 and 3.37; IR (KBr) max/cm–1: 3500–3400 (br, w), 3230 (w), 3120 (w),
2960–2940 (br, w), 1750 (s), 1630 (s), 1580–1560 (br, s), 1440 (m), 1370 (s), 1250–1200
(br, s), 1140 (s), 1080 (s), 1040 (br, s), 920 (m); 1H NMR (DMSO-d6) /ppm: 8.49 (s,
1H, H-2), 8.33 (s, 1H, H-8), 7.86 (d, 2H, J = 8.1 Hz, Ph-b), 7.34 (d, 2H, J = 8.1 Hz,
Ph-c), 6.22 (d, 1H, J = 5.3 Hz H-1',), 5.94 (t, 1H, J = 5.6 Hz, H-2'), 5.57 (t, 1H, J = 5.2
Hz, H-3'), 4.39 (m, 2H, H-4'+H-5'a), 4.25 (m, 1H, H-5'b), 3.35 (brs, NH-6+H2O), 2.35
(s, 3H, CH3-Ts), 2.11 (s, 3H, CH3-Ac), 2.02 (s, 3H, CH3-Ac), 2.01(s, 3H, CH3-Ac); 13C
NMR (DMSO-d6) /ppm: 170.39 (s, C=O), 169.79 (s, C=O), 169.60 (s, C=O), 150.60 (s,
C-6), 149.50 (d, C-2), 149.00 (s, C-4), 142.37 (s, Ph-a), 140.96 (d, C-8), 140.42 (s,
Ph-d), 129.36 (d, Ph-c), 126.92 (d, Ph-b), 123.33 (s, C-5), 85.84 (d, C-1'), 79.78 (d,
C-4'), 72.25 (d, C-2'), 70.17 (d, C-3'), 62.94 (t, C-5'), 21.02 (q, CH3-Ts), 20.55 (q,
CH3-Ac), 20.44 (q, CH3-Ac), 20.25 (q, CH3-Ac).
Anal. calcd. for C23H25N5O9S1 (Mr = 547.53): C 50.45, H 4.60, N 12.79%; found: C
50.52, H 4.69, N 12.58%.
N6-(p-Toluenesulfonyl)adenosine (12)
Nucleoside 11 (90 mg, 0.16 mmol) was dissolved in methanolic ammonia (10
mL) and stirred at room temperature overnight. The solvent was evaporated and the
residue recrystallized from methanol to give 82 mg (99%) of product 12 as white
crystals: m.p. = 104–106 C; Rf = 0.59 (CH2Cl2/MeOH 3:1); UV (MeOH) max/nm: 286.6
(shoulder), 222.5 and 192.0; log / dm3 mol–1 cm–1: 3.23, 3.43 and 3.31; IR (KBr)
max/cm–1: 3600–3200 (br, s), 2960 (s), 1630 (s), 1590 (s), 1560 (s), 1450 (m), 1400 (m),
1360 (m), 1260 (s), 1150–1010 (br, s), 800 (s); 1H NMR (DMSO-d6) /ppm: 8.29 (s, 1H,
H-2), 8.09 (s, 1H, H-8), 7.78 (d, 2H, J = 8.1 Hz, Ph-b), 7.24 (d, 2H, J = 8.1 Hz, Ph-c),
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6.71 (brs, 1H, NH-6), 5.83 (d, 1H, J = 5.9 Hz, H-1'), 5.45 (brs, 2H, OH-5'+OH-2'), 5.19
(brs, 1H, OH-3'), 4.52 (t, 1H, J = 5.5 Hz, H-2'), 4.12 (dd, 1H, J1 = 3.3 Hz, J2 = 4.8 Hz,
H-3'), 3.96 (d, 1H, J = 3.1 Hz, H-4'), 3.60 (m, 2H, H-5'), 2.29 (s, 3H, CH3); 13C NMR
(DMSO-d6) /ppm: 149.91 (C-6+C-2), 149.06 (s, C-4), 142.20 (s, Ph-a), 140.77 (d, C-8),
140.20 (s, Ph-d), 128.78 (d, Ph-c), 126.98 (d, Ph-b), 124.07 (s, C-5), 88.10 (d, C-1'),
85.98 (d, C-4'), 73.75 (d, C-2'), 70.71 (d, C-3'), 61.70 (t, C-5'), 20.96 (q, CH3).
Anal. calcd. for C17H19N5O6S1 (Mr = 421.42): C 48.45, H 4.54, N 16.62%; found: C
48.54, H 4.67, N 16.48%.
9-(2,3,5-Tri-O-acetyl-ß-D-ribofuranosyl)-2-N-(p-toluenesulfonyl)
aminopurine (14)
A mixture of 9-(2,3,5-tri-O-acetyl-ß-D-ribofuranosyl)-2-aminopurine15 (13) (100
mg, 0.25 mmol) and TsCl (171 mg, 0.88 mmol) in anhydrous pyridine (11 mL) was
stirred at 80 C for 23 hours. During that time, one more portion of TsCl (171 mg)
was added (total amount of TsCl was 342 mg, 1.75 mmol). The brown solution was
evaporated and the residue was purified by preparative chromatography (CH2Cl2/MeOH
9:1) to give 65 mg (47%) of 9-(2',3',5'-tri-O-acetyl--D-ribofuranosyl)-2-p-toluenesulfo-
nylaminopurine (14) as a white solid: m.p. = 104 C, Rf = 0.54 (CH2Cl2/MeOH 9:1);
UV (MeOH) max/nm: 286.9 (shoulder), 250.2, 235.0 and 216.9; log / dm3 mol–1 cm–1:
3.60, 3.63, 3.83 and 4.09; IR (KBr) max/cm–1: 3460–3320 (br, m), 3040 (m), 2910–2840
(br, m), 1740 (s), 1600 (br, m), 1500 (w), 1400 (s), 1350 (m), 1240 (br, s), 1160 (s), 1075
(m), 1040 (br, m); 1H NMR (CDCl3) /ppm: 11.80 (brs, 1H, NH-2), 8.85 (s, 1H, H-6),
8.54 (s, 1H, H-8), 7.87 (d, 2H, J = 8.0 Hz, Ph-b), 7.33 (d, 2H, J = 8.0 Hz, Ph-c), 6.13
(d, 1H, J = 5.7 Hz, H-1’), 5.81 (t, 1H, J = 5.8 Hz, H-2’), 5.54 (t, 1H, J = 5.2 Hz, H-3’),
4.37 (m, 2H, H-4’+H-5’a), 4.23 (m, 1H, H-5’b), 2.31 (s, 3H, CH3-Ts), 2,14 (s, 3H, CH3-Ac),
1.99 (s, 6H, 2CH3-Ac); 13C NMR (DMSO-d6) /ppm: 170.23 (s, C=O), 169.55 (s, C=O),
169.36 (s, C=O), 153.17 (s, C-2), 151.94 (s, C-4), 149.44 (d, C-6), 144.11 (d, C-8), 143.21
(s, Ph-a), 137.96 (s, Ph-d), 130.11 (s, C-5), 129.36 (d, Ph-c), 127.69 (d, Ph-b), 85.26 (d,
C-1’), 79.87 (d, C-4’), 72.07 (d, C-2’), 70.34 (d, C-3’), 63.31 (t, C-5’), 21.15 (q, CH3-Ts),
20.65 (q, CH3-Ac), 20.57 (q, CH3-Ac), 20.28 (q, CH3-Ac).
Anal. calcd. for C23H25N5O9S1 (Mr = 547.53): C 50.45, H 4.60, N 12.79%; found: C
50.57, H 4.72, N 12.68%.
9-(ß-D-Ribofuranosyl)-2-N-(p-toluenesulfonyl)aminopurine (15)
Nucleoside 14 (70 mg, 0.13 mmol) was dissolved in methanolic ammonia (10
mL) and stirred at room temperature for three days. The solvent was evaporated
and the residue was purified by preparative chromatography (CH2Cl2/MeOH 3:1),
yielding 9-(ß-D-ribofuranosyl)-2-N-(p-toluenesulfonyl)aminopurine (15) 52 mg (98%):
m.p. = 92-94 C, Rf = 0.52 (CH2Cl2/MeOH 3:1); UV (MeOH) max/nm: 313.4, 257.6,
225.8 and 201.7; log / dm3 mol–1 cm–1: 3.65, 3.91, 4.29 and 4.20; IR (KBr) max/cm–1:
3500–3200 (br, s), 2940–2820 (br, m), 1650 (br, m), 1600–1570 (br, m), 1500 (m),
1390–1320 (br, m), 1245 (s), 1180–1000 (br, s), 780 (s); 1H NMR (DMSO-d6) /ppm:
8.78 (s, 1H, H-6), 8.54 (s, 1H, H-8), 7.89 (d, 2H, J = 7.9 Hz, Ph-b), 7.32 (d, 2H, J = 7.7
Hz, Ph-c), 6.70 (brs, 1H, NH-2), 5.87 (d, 1H, J = 5.3 Hz H-1’), 5.60–5.31 (br, 2H,
OH-5’+OH-2’), 5.30–5.18 (br, 1H, OH-3’), 4.49 (t, 1H, J = 4.9 H-2’, Hz), 4.15 (brs, 1H,
H-3’), 3.95 (d, 1H, J = 3.3 Hz, H-4’), 3.59 (m, H-5’+H2O), 2.30 (s, 3H, CH3-Ts); 13C
NMR (DMSO-d6) /ppm: 153.95 (s, C-2), 152.32 (s, C-4), 148.97 (d, C-6), 144.00 (d,
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C-8). 142.70 (s, Ph-a), 138.50 (s, Ph-d), 129.66 (s, C-5), 129.20 (d, Ph-c), 127.96 (d,
Ph-b), 87.01 (d, C-1’), 85.60 (d, C-4’), 73.67 (d, C-2’), 70.41 (d, C-3’), 61.39 (t, C-5’),
21.18 (q, CH3-Ts).
Anal. calcd. for C17H19N5O6S1 (Mr = 421.42): C 48.45, H 4.54, N 16.62%; found: C
48.63, H 4.69, N 16.38%. MS (EI) exact mass calcd for C17H19N5O6S1+H+ m/e 422.112883,
found 422.119945.
Mass spectra:
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TABLE II
The 70 eV EI mass spectra of 2-5, 8, 9, and 11 at 100 s and 1 s time delay
com-
pound
time delay
100 s 1 s
M+
(%)
M+H+
(%)
fragment
ions (%)
M+
(%)
M+H+
(%)
fragment
ions (%)
2 289 (22) 290 (0) 272 (3) 289 (3) 290 (100)
262 (2) M-HCN+ 226 (32)
M+H -SO2+225 (100) M-SO2+
224 (17) M-SO2H+
209 (4) other ions of
low intensity198 (9)
183 (24)
170 (3)
155 (6)
3 443 (0) 444 (0) 378 (72) M-SO2H+ 443 (0) 444 (100) 379 (12)
M+H-SO2+262 (5)
224 (100)
M-SO2PhMe-SO2+
378 (48)
329 (7)
155 (17) 290 (8)
149 (21) 224 (9)
222 (8)
140 (15)
4 289 (2) 290 (0) 262 (2) M-HCN+ 289 (0) 290 (100)
225 (20) M-SO2+ 224 (31)
224 (100)M-SO2H+ 202 (7)
202 (10)
149 (18)
5 213 (100) 214 (20) 148 (3) M-SO2H+ 213 (0) 214 (100)
135 (14)
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com-
pound
time delay
100 s 1 s
M+
(%)
M+H+
(%)
fragment
ions (%)
M+
(%)
M+H+
(%)
fragment
ions (%)
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262 (32)
213 (100)
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149 (27)
135 (99)
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SA@ETAK
Sinteza, te NMR i MS studija novih N-Sulfonil-derivata purina
Biserka @ini}, Irena Krizmani}, Dra`en Viki}-Topi},
Dunja Srzi} i Mladen @ini}
Tosiliranje i meziliranje adenina (1) na sobnoj temperaturi regioselektivno daje
N9-sulfonilpurine 2 i 5. Suvi{ak TsCl ili MsCl, te povi{ena temperatura reakcije
vode do nestabilnih N6,N9-disulfonil-produkata 3 i 6, koji se lagano transformiraju u
odgovaraju}i N6-monosulfonil-produkt 4. Tako|er su sintetizirani N-sulfonil-derivati
purinskih nukleozida 12 i 15. Mjesta sulfoniliranja kao i prostorni raspored supsti-
tuenata utvr|eni su s pomo}u 1D i 2D NMR spektroskopije. MS spektri pokazuju
neo~ekivanu pregradnju protoniranih molekulnih iona do koje dolazi zbog gubitka SO2.
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